Compare Edwards Lifesciences Corporation Common Stock (EW) vs ING Groep NV (ING) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs ING Groep NV — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.24 (market cap $48.56B), while ING Groep NV trades at $33.31 (market cap $93.76B). The key difference: ING Groep NV is the larger of the two by market cap, and ING Groep NV pays a 3.95% dividend while Edwards Lifesciences Corporation Common Stock pays none. Which is the better fit depends on your goals.
| EW | ING | |
|---|---|---|
Market Cap | $48.56B | $93.76B |
Volume | 6,520,488 | 4,620,220 |
Sector | Health | Financials |
52-Week High | $95.18 | $37.27 |
52-Week Low | $72.65 | $23.66 |
Enterprise Value | $45.01B | $236.48B |
Typical Hold Time | — | 93 Days |
Dividend Yield | — | 3.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ING trades at $33.92, down 2.81% on the day, with a bearish technical signal from moving averages and oscillators. The company reported revenue of $22.90 billion in 2025, with net income of $6.33 billion and a net margin of 28.34%. Recent earnings beats and a raised 2027 ROE target above 16% highlight operational strength, though cash flow trends show persistent net outflows.
The outlook is mixed: strong profitability and analyst consensus (64.71% buy ratings) support upside, but bearish technicals and regulatory scrutiny in Australia pose risks. Valuation appears reasonable with a P/E of 13.09, offering a potential entry for long-term investors focused on execution of growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
